Search Results - "Bissonnette, Robert"

The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial.

Authors: Bissonnette, Robert Vender, Ronald Pinter, Andreas et al.

Source: Journal of Dermatological Treatment. Dec2025, Vol. 36 Issue 1, p1-7. 7p.

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.

Authors: Simpson, Eric L. Bissonnette, Robert Chiesa Fuxench, Zelma C. et al.

Source: Journal of Dermatological Treatment. Dec2024, Vol. 35 Issue 1, p1-10. 10p.

Gut microbiome of patients with nonatopic chronic hand eczema (CHE) is distinct and enriched in immunomodulatory bacteria species compared with patients with atopic CHE and healthy individuals.

Authors: Bissonnette, Robert Salem, Youssef Palijan, Ana et al.

Source: British Journal of Dermatology. Jun2026, Vol. 194 Issue 6, p1161-1163. 3p.

Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials.

Authors: Bissonnette, Robert Albreiki, Fatima Ehst, Benjamin D. et al.

Source: American Journal of Clinical Dermatology. Jan2026, Vol. 27 Issue 1, p203-208. 6p.

Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials.

Authors: Bissonnette, Robert Albreiki, Fatima Ehst, Benjamin D. et al.

Source: American Journal of Clinical Dermatology. Jan2026, Vol. 27 Issue 1, p199-202. 4p.

Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.

Authors: Bissonnette, Robert Soung, Jennifer Hebert, Adelaide A. et al.

Source: New England Journal of Medicine. 11/6/2025, Vol. 393 Issue 18, p1784-1795. 12p.

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.

Authors: Burden, A. David Bissonnette, Robert Navarini, Alexander A. et al.

Source: Dermatology & Therapy. Oct2023, Vol. 13 Issue 10, p2279-2297. 19p.

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.

Authors: Gold, Linda Stein Armstrong, April W Bissonnette, Robert et al.

Source: Lancet. 9/27/2025, Vol. 406 Issue 10510, p1363-1374. 12p.

Subjects: Psoriasis, Interleukin-23, Treatment effectiveness, Clinical trials, Safety, Randomized controlled trials, Johnson & Johnson (Company), Oral drug administration

Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials.

Authors: Bissonnette, Robert Jankicevic, Jasmina Saint-Cyr Proulx, Etienne et al.

Source: Journal of Clinical Medicine. Jun2023, Vol. 12 Issue 11, p3805. 7p.

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.

Authors: Bissonnette, Robert Maari, Catherine Tsianakas, Athanasios et al.

Source: Dermatology & Therapy. Dec2021, Vol. 11 Issue 6, p2179-2193. 15p.

A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis: Ruxolitinib Cream: Pediatric Maximum-Use Trial: L. S. Gold et al.

Authors: Stein Gold, Linda Bissonnette, Robert Forman, Seth et al.

Source: American Journal of Clinical Dermatology. Mar2025, Vol. 26 Issue 2, p275-289. 15p.

Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.

Authors: Bissonnette, Robert Warren, Richard B Pinter, Andreas et al.

Source: Lancet. Aug2024, Vol. 404 Issue 10451, p461-473. 13p.

Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy–Fatigue and pain‐Visual Analogue Scale in patients with generalized pustular psoriasis.

Authors: Burden, A. David Bissonnette, Robert Anatchkova, Milena et al.

Source: Journal of the European Academy of Dermatology & Venereology. Jul2024, Vol. 38 Issue 7, p1383-1390. 8p.

Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.

Authors: Bissonnette, Robert DuBois, Janet Facheris, Paola et al.

Source: Allergy. Apr2024, Vol. 79 Issue 4, p924-936. 13p.

The vIGA‐AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council.

Authors: Bissonnette, Robert Simpson, Eric Eichenfield, Lawrence F. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Mar2024, Vol. 38 Issue 3, pe291-e295. 5p.

An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.

Authors: Bissonnette, Robert Pinter, Andreas Ferris, Laura K. et al.

Source: New England Journal of Medicine. 2/8/2024, Vol. 390 Issue 6, p510-521. 12p.

Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Authors: Gooderham, Melinda J. Bissonnette, Robert Kalia, Sunil et al.

Source: Journal of Cutaneous Medicine & Surgery. Nov2023, Vol. 27 Issue 6, p594-600. 7p.

Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.

Authors: Bissonnette, Robert Vasist, Lakshmi S. Bullman, Jonathan N. et al.

Source: Clinical Pharmacology in Drug Development. Jun2018, Vol. 7 Issue 5, p524-531. 8p.

Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI).

Authors: Burden, A. David Bissonnette, Robert Lebwohl, Mark G. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Jul2023, Vol. 37 Issue 7, p1327-1335. 9p.

Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis (ADVISE).

Authors: Silverberg, Jonathan I. Bissonnette, Robert Kircik, Leon et al.

Source: Journal of the European Academy of Dermatology & Venereology. Jul2023, Vol. 37 Issue 7, p1366-1374. 9p.